The 36-month beta value for EYPT is at 1.52. Analysts have varying views on the stock, with 9 analysts rating it as a “buy,” 4 rating it as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for EYPT is 61.83M, and currently, shorts hold a 16.72% of that float. The average trading volume for EYPT on January 16, 2025 was 977.65K shares.
EYPT) stock’s latest price update
EyePoint Pharmaceuticals Inc (NASDAQ: EYPT) has seen a rise in its stock price by 2.99 in relation to its previous close of 7.69. However, the company has experienced a -13.06% decline in its stock price over the last five trading sessions. globenewswire.com reported 2025-01-16 that WATERTOWN, Mass., Jan. 16, 2025 (GLOBE NEWSWIRE) — EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious retinal diseases, today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company’s 2023 Long-Term Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4).
EYPT’s Market Performance
EyePoint Pharmaceuticals Inc (EYPT) has experienced a -13.06% fall in stock performance for the past week, with a 6.17% rise in the past month, and a -19.84% drop in the past quarter. The volatility ratio for the week is 9.42%, and the volatility levels for the past 30 days are at 8.17% for EYPT. The simple moving average for the past 20 days is 1.73% for EYPT’s stock, with a -24.56% simple moving average for the past 200 days.
Analysts’ Opinion of EYPT
Many brokerage firms have already submitted their reports for EYPT stocks, with Citigroup repeating the rating for EYPT by listing it as a “Buy.” The predicted price for EYPT in the upcoming period, according to Citigroup is $33 based on the research report published on January 07, 2025 of the current year 2025.
Jefferies gave a rating of “Buy” to EYPT, setting the target price at $15 in the report published on August 28th of the previous year.
EYPT Trading at -9.81% from the 50-Day Moving Average
After a stumble in the market that brought EYPT to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -74.44% of loss for the given period.
Volatility was left at 8.17%, however, over the last 30 days, the volatility rate increased by 9.42%, as shares surge +4.14% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -34.29% lower at present.
During the last 5 trading sessions, EYPT fell by -13.01%, which changed the moving average for the period of 200-days by -60.90% in comparison to the 20-day moving average, which settled at $7.79. In addition, EyePoint Pharmaceuticals Inc saw 6.31% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at EYPT starting from ANTHONY P. ADAMIS, who proposed sale 67,100 shares at the price of $10.04 back on Oct 23 ’24. After this action, ANTHONY P. ADAMIS now owns shares of EyePoint Pharmaceuticals Inc, valued at $673,355 using the latest closing price.
David R. Guyer, the Former Director of EyePoint Pharmaceuticals Inc, proposed sale 36,975 shares at $8.92 during a trade that took place back on Oct 14 ’24, which means that David R. Guyer is holding shares at $329,817 based on the most recent closing price.
Stock Fundamentals for EYPT
Current profitability levels for the company are sitting at:
- -2.56 for the present operating margin
- 0.91 for the gross margin
The net margin for EyePoint Pharmaceuticals Inc stands at -2.27. The total capital return value is set at -0.46. Equity return is now at value -74.68, with -44.94 for asset returns.
Based on EyePoint Pharmaceuticals Inc (EYPT), the company’s capital structure generated 0.09 points at debt to capital in total, while cash flow to debt ratio is standing at -5.18.
Currently, EBITDA for the company is -69.0 million with net debt to EBITDA at 0.57. When we switch over and look at the enterprise to sales, we see a ratio of 10.39. The receivables turnover for the company is 120.93for trailing twelve months and the total asset turnover is 0.15. The liquidity ratio also appears to be rather interesting for investors as it stands at 5.50.
Conclusion
In conclusion, EyePoint Pharmaceuticals Inc (EYPT) has had a mixed performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
